{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:27:24Z","timestamp":1793910444213,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.chest.2023.11.038","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T17:45:21Z","timestamp":1701279921000},"page":"1082-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment"],"prefix":"10.1016","volume":"165","author":[{"given":"Sanne M.H.","family":"Zweijpfenning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Magis-Escurra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6912-4163","authenticated-orcid":false,"given":"Ralf","family":"Stemkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-4491","authenticated-orcid":false,"given":"Bram","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-1075","authenticated-orcid":false,"given":"Wouter","family":"Hoefsloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2023.11.038_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2023.11.038_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1586\/14787210.2013.830413","article-title":"Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence","volume":"11","author":"van Ingen","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.chest.2023.11.038_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2023.11.038_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","article-title":"Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort","volume":"131","author":"Zweijpfenning","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2023.11.038_bib5","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in Mycobacterium avium complex pulmonary disease: an expert panel survey","volume":"73","author":"van Ingen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.chest.2023.11.038_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijantimicag.2013.05.007","article-title":"Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections","volume":"42","author":"Magis-Escurra","year":"2013","journal-title":"J\u00a0Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.chest.2023.11.038_bib7","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.chest.2023.11.038_bib8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.chest.2023.11.038_bib9","first-page":"462","article-title":"Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d\u2019Etude et de Traitement des Infections \u00e0 Mycobact\u00e9ries","volume":"2","author":"Roussel","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.chest.2023.11.038_bib10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2023.11.038_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.chest.2023.11.038_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.chest.2023.11.038_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.chest.2023.11.038_bib14","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.chest.2023.11.038_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2023.11.038_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.chest.2023.11.038_bib17","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","article-title":"Clofazimine pharmacokinetics in patients with TB: dosing implications","volume":"75","author":"Abdelwahab","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.chest.2023.11.038_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2023.11.038_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"Van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2023.11.038_bib20","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/AAC.02854-15","article-title":"Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease","volume":"60","author":"Deshpande","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.chest.2023.11.038_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.chest.2023.11.038_bib22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201711-2333OC","article-title":"Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis","volume":"198","author":"Dheda","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.11.038_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.chest.2021.08.046","article-title":"Mycobacterium growth indicator tube time-to-positivity can serve as an early biomarker of treatment response in Mycobacterium avium complex pulmonary disease","volume":"161","author":"Danho","year":"2022","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2023.11.038_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01386-2018","article-title":"NTM-NET. Clofazimine does not lead to significant QT interval prolongation: a multicentre study","volume":"52","author":"Zweijpfenning","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2023.11.038_bib25","doi-asserted-by":"crossref","first-page":"00207","DOI":"10.1183\/23120541.00207-2021","article-title":"The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands","volume":"7","author":"Schildkraut","year":"2021","journal-title":"ERJ Open Res"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223058300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223058300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:56:56Z","timestamp":1717577816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223058300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0012369223058300"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.11.038","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}